Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D001775:Blood Circulation / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects*; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008660:Metabolism / Q000187:drug effects*; D009200:Myocardial Contraction / Q000187:drug effects; D010100:Oxygen / Q000097:blood*; D010974:Platelet Aggregation / Q000187:drug effects; D012083:Renin / Q000097:blood*; D012849:Sinoatrial Node / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D012083:Renin; D010100:Oxygen